Here is a breakdown of the 10 drugs employer-sponsored health plans paid the most for in 2017:
1. Humira ($4.9 billion)
2. Enbrel ($2.4 billion)
3. Copaxone ($1.2 billion)
4. Tecfidera ($1.1 billion)
5. Harvoni ($1 billion)
6. Truvada ($900 million)
7. Stelara ($900 million)
8. Vyvanse ($900 million)
9. Lantus Solostar ($800 million)
10. Gilenya ($700 million)
Read the full report here.
More articles on pharmacy:
How hospitals can better align the pharmacy to achieve its strategic goals
Google sister-company Verily partners with big pharma for clinical trials
Merck’s Keytruda fails late-stage trial as standalone treatment for breast cancer
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
